Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wonder if they used Lung on a chip for the study and mice of course :)
Results: Both types of adjuvanted virosomes coupled to Bet v 1 COPs triggered a boosted Th1 immunity. Given a more favourable safety profile, Vir. A-Bet v 1 COPs were further evaluated and shown to able to fully reverse asthma symptoms and lung inflammation in a sublingual therapeutic model of birch pollen allergy.
https://pubmed.ncbi.nlm.nih.gov/33368719/
News - TBVI
www.tbvi.eu › news-events › news
In Uncategorized Posted March 9, 2021 European Research Infrastructure project TRANSVAC2 | New Vaccines Faster: Open Call for expert services and support to vaccine development! Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities not readily available at a single organization.
European Research Infrastructure project TRANSVAC2 | New Vaccines Faster: Open Call for expert services and support to vaccine development!
Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities not readily available at a single organization. TRANSVAC2, European Research Infrastructure project facilitates access to these skills and capacities across the vaccine R&D pipeline. For the last 3 years we supported over 40 projects from researchers worldwide to boost the development of their vaccines. Among granted projects we have supported human and veterinary vaccine candidates for infectious diseases (viral, including COVID-19; bacterial; parasitic), cancer, allergies and adjuvant development.
https://www.tbvi.eu/european-research-infrastructure-project-transvac2-new-vaccines-faster-open-call-for-expert-services-and-support-to-vaccine-development/
Remember KIM-1/TIM VIROSOME: Second Study from University Of Oxford
SUMMARY
This study highlights how uptake of SARS-Cov-2 virosomes into human alveolar basal epithelial cells and pig kidney lines was significantly reduced upon blockade of KIM-1. Equally, the uptake of SARS-CoV-2 virosomes increased upon upregulation of KIM-1 on human tubuloids and KIM-1 was shown to bind to SARS-CoV-2 spike protein ectodomain in-vitro. Overall, these observations suggest that KIM-1 may be a receptor for SARS-CoV-2 in both the lung and kidney.
Finally, KIM-1 was shown to bind to the SARS-CoV-2 spike protein ectodomain and GST-RBD in-vitro, with an EC50 of 19nM and 10nM respectively.
https://www.immunology.ox.ac.uk/covid-19/covid-19-immunology-literature-reviews/kim-1-tim-1-is-a-receptor-for-sars-cov-2-in-lung-and-kidney
KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney
First Study done by Division of Renal Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
https://www.medrxiv.org/content/10.1101/2020.09.16.20190694v1
Article
Published: 26 February 2021
SARS-CoV-2 spike D614G change enhances replication and transmission
Bin ZhouView ORCID ID profile
These authors contributed equally: Bin Zhou, Tran Thi Nhu Thao, Donata Hoffmann, Adriano Taddeo
CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Martin BeerView ORCID ID profile
These authors jointly supervised this work: Charaf Benarafa, David E. Wentworth, Volker Thiel, Martin Beer
Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany
Affiliations
CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Bin Zhou, Xiaoyu Fan, Li Wang, Jaber Hossain, Malania Wilson, Matthew Keller, Thomas J. Stark, John R. Barnes & David E. Wentworth
Institute of Virology and Immunology (IVI), Bern and Mittelhäusern, Bern, Switzerland
Tran Thi Nhu Thao, Adriano Taddeo, Nadine Ebert, Silvio Steiner, Jenna N. Kelly, Jasmine Portmann, Lisa Thomann, Hanspeter Stalder, Ronald Dijkman, Charaf Benarafa & Volker Thiel
Department of Infectious Diseases and Pathobiology, Vetsuisse
Faculty, University of Bern, Bern, Switzerland
Tran Thi Nhu Thao, Adriano Taddeo, Nadine Ebert, Fabien Labroussaa, Silvio Steiner, Jenna N. Kelly, Jasmine Portmann, Bettina Salome Trüeb, Lisa Thomann, Hanspeter Stalder, Ronald Dijkman, Joerg Jores, Charaf Benarafa & Volker Thiel
Graduate School for Biomedical Science, University of Bern, Bern, Switzerland
Tran Thi Nhu Thao & Silvio Steiner
Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany
Donata Hoffmann, Anne Pohlmann, Jacqueline King, Nico Joel Halwe, Lorenz Ulrich, Bernd Hoffmann & Martin Beer
Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
Fabien Labroussaa, Bettina Salome Trüeb & Joerg Jores
Battelle Memorial Institute, Atlanta, Georgia, United States of America
Xudong Lin & Dan Cui
Institute of Cell Biology, University of Bern, Bern, Switzerland
Berta Pozzi
COMPATH, Institute of Animal Pathology, University of Bern, Bern, Switzerland
Simone de Brot
Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, United States of America
Nannan Jiang
Institute for Infectious Diseases, University of Bern, Bern, Switzerland
Ronald Dijkman
Corresponding authors
Correspondence to Charaf Benarafa or David E. Wentworth or Volker Thiel or Martin Beer.
https://www.nature.com/articles/s41586-021-03361-1
SARS-CoV-2 mutations in competition
Date:
February 26, 2021
Source:
University of Bern
Summary:
How dangerous are new mutations of the SARS-CoV-2 virus? Researchers have developed an approach that can accurately assess the transmissibility of new virus mutants
https://www.sciencedaily.com/releases/2021/02/210226103828.htm
Pfizer (PFE +0.5%) says its $6 tender offer for shares of Icagen (ICGN +0.2%) is successful...
Sep. 06, 2011 1:45 PM ETPfizer Inc. (PFE)By: Clark Schultz, SA News Editor
Pfizer (PFE +0.5%) says its $6 tender offer for shares of Icagen (ICGN +0.2%) is successful after it needed two extensions to get a controlling interest of the company. A new offering period was initiated by the company at the same $6 price, expiring next Monday.
https://seekingalpha.com/news/90250
Round Enterprises, Ltd.
Insider Trading Report
SEC.report › Insider Transaction Feed › Round Enterprises, Ltd. › Insider Trading
Round Enterprises, Ltd. has traded MYMX, ICGN while serving in roles requiring financial disclosures. The following positions have been held:
>10% Owner; 2015 at MYMETICS CORP
>10% Owner; 2005 at ICAGEN INC
Icagen, Inc.
4222 Emperor Blvd., Suite 350
Durham, North Carolina 27703
Telephone: (919) 941- 5206
https://sec.report/CIK/0001300013/Insider-Trades
https://sec.report/Document/0001213900-20-005122/
IS ICAGEN INC COMING BACK
https://www.icagen.com/
https://www.ligand.com/technologies/icagen?__hstc=148209768.8b458ae55625b502947ae7f3ddbb9d42.1616341812148.1616341812148.1616341812148.1&__hssc=148209768.2.1616341812148&__hsfp=1077475702
Round Enterprises Ltd.
NEXT RENEWAL DATE: 2022/02/23 13:29:11 +01:00
Round Enterprises Ltd. is a company located in Virgin Islands (British), VG1110 Road Town at Mill Mall. Round Enterprises Ltd. has an ACTIVE entity status and an ISSUED LEI code. The Legal Entity Identifier code of Round Enterprises Ltd. is 254900MEDL9YXW8DDZ86. The legal form of this company is 6EH6 and is subject to the jurisdiction of VG law.
https://lei.info/254900MEDL9YXW8DDZ86
I wonder if Round Enterprises Ltd updated (Renewal)
Last Update Date 2021-02-11 15:31:43
https://lei.report/LEI/254900MEDL9YXW8DDZ86
Received 7 January 2021, Revised 8 March 2021, Accepted 11 March 2021, Available online 14 March 2021.
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate
Author links open overlay pane lWen-Hsiang ChenabJunfeiWeiaRakhi TyagiKunduaRakeshAdhikariaZhuyunLiuaJungsoonLeeaLeroyVersteegaCristinaPovedaaBrianKeeganaMaria JoseVillaraAna C.de Araujo LeaoaJoanne AltieriRiveraaPortia M.GillespieaJeroenPolletabUlrichStrychabBinZhanabPeter J.HotezabcdMaria ElenaBottazziabcd
a
Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA
b
Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA
c
Department of Biology, Baylor University, Waco, TX, USA
d
James A. Baker III Institute for Public Policy, Rice University, Houston, TX, USA
https://www.sciencedirect.com/science/article/pii/S0304416521000519#bb0130
New adjuvant helps induce long-lasting immunity against HIV
Researchers at the Yerkes National Primate Research Center and the Emory Vaccine Center (EVC) are first to show a new adjuvant, 3M-052, helps induce long-lasting immunity against HIV. The study results are published today in Science Immunology.
https://www.news-medical.net/news/20200620/New-adjuvant-helps-induce-long-lasting-immunity-against-HIV.aspx
Mymetics Corporation (MYMX): 3M-052 as an adjuvant for a PLGA ...
investorshub.advfn.com › boards › read_msg
3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine... (TLR) 7/8 agonist 3M-052 in combination with the Leishmania donovani 36-kDa nucleoside...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158964269
New GMP manufacturing processes to obtain thermostable HIV-1 ...
pubmed.ncbi.nlm.nih.gov › 32435515
The HIV-1 gp41-derived antigens anchored in the virosome membrane, along with the adjuvant 3M-052 (TLR7/8 agonist) on the same particle, served as a candidate vaccine for the proof of concept for establishing manufacturing processes, which can be directly applied or adapted to other virosomal vaccines or lipid-based particles.
https://pubmed.ncbi.nlm.nih.gov/32435515/
Hungry Hippo
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151753105
Sloppy Drunk!!
Wonder if the Big Bonanza is coming?
Maria Elena Bottazzi - Florida Physician
floridaphysician.med.ufl.edu › tag › maria-elena
Maria Elena Bottazzi. ... UF Health is a collaboration of the University of Florida Health Science Center, Shands hospitals and other health care entities.
https://floridaphysician.med.ufl.edu/tag/maria-elena-bottazzi/
https://profiles.gulfcoastconsortia.org/profilesystem/editprofile.php?pid=4928&onlyview=1
Do you Believe in COVID-19 Vaccines Expert’s? LOL
COVID-19 Vaccines Expert’s Summit
ghc.fiu.edu › _assets › docs
University of Bern Switzerland Dr. Peter Hotez Dean, National School of Tropical Medicine, Baylor College of Medicine Houston, Texas, USA Dr. Annelies Wilder-Smith Member, WHO-IVB-SAGE Working Group on COVID-19 Vaccines London, UK 10:20 a.m. 12:15 p.m. Moderator Dr. María Elena Bottazzi Associate Dean, National School of Tropical Medicine,
Dr. Peter Hotez
Dean, National School of Tropical Medicine, Baylor
College of Medicine
Houston, Texas, USA
Moderator
Dr. María Elena Bottazzi
Associate Dean, National School of Tropical Medicine,
Baylor College of Medicine
Houston, Texas, USA
Dr. Oscar Franco
Professor of Epidemiology and Public Health,
Institute of Social and Preventive Medicine (ISPM),
University of Bern
Switzerland
https://ghc.fiu.edu/_assets/docs/final-english-agenda-covid191.pdf
Merck Group is called Merck KGaA, Darmstadt, Germany in the US and Canada. In addition, it also operates three businesses in US and Canada; EMD Millipore, EMD Serono and EMD Performance Materials. In all other countries the company is called Merck. Merck & Cie is a subsidiary of Merck KGaA in Darmstadt, which has its headquarters in Altdorf (UR). The branch in Schaffhausen concentrates on the development and production of active pharmaceutical ingredients (APIs) and high-purity substances for active substance transport or active substance carrying systems (Drug Delivery). The company is the world leading supplier of reduced folates. Merck & Cie in Schaffhausen employs a staff of more than one hundred.
Merck & Cie Schaffhausen, established in 1952, is a development and manufacturing site for active pharmaceutical ingredients and drug delivery compounds serving the global chemical and pharmaceutical markets.
https://www.swissbiotech.org/listing/merck-cie/
New GMP manufacturing processes to obtain thermostable HIV-1 ...
www.nature.com › articles › s41541/020/0190-9
May 18, 2020 · Fluorescent placebo virosomes for in vitro studies were produced by inserting the 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE, Merck & Cie, Schaffhausen, Switzerland) conjugated to ...
Author: Mario Amacker, Charli Smardon, Laura Mason, Jack Sorrell, Kirk Jeffery, Michael Adler, Farien Bhoela...
Cited by: 1
Merck is supporting the fight against the Covid-19 pandemic in multiple ways
As a science and technology company, Merck also helped to meet the global challenges posed by Covid-19 in many different ways in the second quarter. The company is collaborating with more than 45 vaccine developers worldwide, including Baylor College of Medicine in Houston, Texas, among others. In June, the company announced that the U.S. Food and Drug Administration (FDA) approved the investigational new drug application (IND) for the investigational compound M5049 for the treatment of patients with Covid-19 pneumonia. In this context, a Phase II randomized, controlled clinical study evaluating the safety and efficacy of M5049 in this patient population was started at the end of July. In addition, the company donated larger amounts of disinfectant and two million FFP2 protective face masks. “In the battle against Covid-19, we will continue to closely support our customers and partners in the science space. Collaboration across borders and sectors is key in effectively fighting the pandemic,” said Oschmann.
https://www.bionity.com/en/news/1167478/merck-remains-on-course-in-a-challenging-environment.html
MRCG.BE - Merck KGaA Profile | Reuters
www.reuters.com › companies › MRCG
Stefan Oschmann. Chairman of the Executive Board and Chief Executive Officer ... Baylor College Announce Covid-19 Vaccine Collaboration * MERCK AND BAYLOR COLLEGE OF MEDICINE COLLABORATE TO ...
https://www.reuters.com/companies/MRCG.BE
Mr. Oschmann shares his view on the role of Bill Gates in the worldwide fight against the disease. When it comes to the WHO, he argues that while the organization is flawed it is an essential factor in global health and needs to be depoliticalized.
https://www.future-of-leadership.org/podcast-leadership-2/
From last post m5049 compound Merck!
This was the guy that came up with the compound a Merck Guy!!
Shinji OKITSU | Senior Scientist | PhD | Immunology
https://www.researchgate.net/publication/215637434_Preclinical_profiling_of_the_immunogenicity_of_a_two-component_subunit_malaria_vaccine_candidate_based_on_virosome_technology
Second Quarter: Merck Remains on Course in a Challenging ...
www.merckgroup.com › investors › reports-and
Aug 06, 2020 · Baylor College of Medicine in Houston, Texas, among others. In June, the company announced that the U.S. Food and Drug Administration (FDA) approved the investigational new drug application (IND) for the investigational compound M5049 for the treatment of patients with Covid-19 pneumonia. In this context, a Phase II
https://www.emdgroup.com/en/404.html
OOOPS. Something Went Wrong.
Here we go!!
Company is supporting the fight against the Covid-19 pandemic in multiple
ways
As a science and technology company, Merck KGaA, Darmstadt, Germany, also
helped to meet the global challenges posed by Covid-19 in many different ways in
the second quarter. The company is collaborating with more than 45 vaccine
developers worldwide, including Baylor College of Medicine in Houston, Texas,
among others. In June, the company announced that the U.S. Food and Drug
Administration (FDA) approved the investigational new drug application (IND) for
the investigational compound M5049 for the treatment of patients with Covid-19
pneumonia. In this context, a Phase II randomized, controlled clinical study
evaluating the safety and efficacy of M5049 in this patient population was started
at the end of July. In addition, the company donated larger amounts of disinfectant
and two million N95 medical grade masks. “In the battle against Covid-19, we will
continue to closely support our customers and partners in the science space.
Collaboration across borders and sectors is key in effectively fighting the pandemic,”
said Oschmann.
https://www.emdgroup.com/investors/reports-and-financials/earnings-materials/2020-q2/us/2020-Q2-Press-Release-NA.pdf
Nice Find Friend!! Here's a little more!
The single largest independent vaccine company in the world.
cours-examens.org › images › Etudes_superieures
Merck & Co., Inc. May 2003 PER.C6 Pre-clinical Novartis Sep. 2006 Aug. 2004 STAR ... using Crucell's MAbstract® and PER.C6® technology 39. Pipeline 19 mars 2009 40
https://cours-examens.org/images/Etudes_superieures/Genie_pharmaceutique/Master_GP/Stage_en_entreprise/Crucell-2009-.pdf
Crucell and Merck & Co. Sign PER.C6(tm) Licensing Agreement ...
www.globenewswire.com › news-release › 2003/06/03
Jun 03, 2003 · Other partners include Merck & Co. for a HIV vaccine and the National Institutes of Health (NIH) for an Ebola vaccine. In addition, Crucell has over 25 licensees for its PER.C6(tm) technology.
https://www.outsourcing-pharma.com/Article/2007/10/15/Crucell-up-on-MedImmune-deal#
ClinicalTrials.gov: COVID-19 | Last update posted in the last ...
clinicaltrials.gov s. ct2 results
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE) ... Internet-based self-help after 3 weeks Sponsor: University of Bern Active, ...
This is what it showed/ LMAO Hiding It!!!!
https://clinicaltrials.gov/ct2/results/rss.xml?cond=COVID-19&lupd_s=06%2F12%2F2020&lupd_d=14&count=1000
This is Better!! But not University Of Bern
https://clinicaltrials.gov/ct2/show/NCT04448756
HALF-YEARLY FINANCIAL REPORT 2020 / Merck KGaA Darmstadt Germany
On May 27, we announced an extension of our ongoing
collaboration with Baylor College of Medicine in Houston,
Texas, USA. Together we are working on a process development approach to accelerate the production of Baylor’s
Covid-19 vaccine candidates, including the vaccine candidate RBD219-N1, which is expected to enter clinical trials
later this year. We will help to accelerate their suitability for
large-scale manufacturing. The collaboration will focus on
improvements to production efficiency, yield, robustness,
scalability and costs.
• On June 25, we announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug
application (IND) for our investigational compound M5049
for the treatment of patients with Covid-19 pneumonia. We
will now initiate a Phase II randomized, controlled clinical
study to evaluate the safety and efficacy of M5049 in this
patient population. More information on this can be found
under ?Healthcare”.
https://www.emdgroup.com/investors/reports-and-financials/earnings-materials/2020-q2/us/2020-Q2-Report-NA.pdf
Discovery of M5049: A Novel Selective TLR7/8 Inhibitor for Treatment of Autoimmunity
Shinji OKITSU | Senior Scientist | PhD | Immunology
www.researchgate.net › profile › Shinji-Okitsu
O37 M5049, a novel potent and selective inhibitor of toll-like receptors 7 and 8 (TLR 7/8) ... MMV Malaria Box Compounds. Data. Jan 2016; David M. Plouffe. ... A Randomized Placebo-Controlled
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159589372
Kuehne+Nagel Group
Sinovac relies on Kuehne+Nagel’s pharma network for Covid-19 vaccine distribution
https://newsroom.kuehne-nagel.com/sinovac-relies-on-kuehnenagels-pharma-network-for-covid-19-vaccine-distribution/
Tobias B. Staehelin proposed for election to the Board of Directors of Kuehne+Nagel Updated on March 3rd, 2021 at 15:44 IST
Tobias B. Staehelin will be proposed for election to the Board of Directors of Kuehne + Nagel International AG at the Annual General Meeting on May 4, 2021. Staehelin, born in 1978, is currently chief executive officer of C. Haushahn GmbH & Co. KG in Stuttgart and member of the Management Board of Schindler Deutschland AG & Co. KG in Berlin. He is also a member of the Board of Directors of Schindler Holding AG and Schindler Aufzüge AG. As of April 1, 2021, he was appointed head Group Human Resources on the Schindler Group Executive Committee.
I would think a relationship to Dr. Thomas Staehelin :)
https://www.stattimes.com/news/tobias-b-staehelin-proposed-for-election-to-the-board-of-directors-of-kuehnenagel-logistics/
https://news.europawire.eu/dominik-burgy-nominated-as-a-new-member-of-the-board-of-directors-of-kuehne-nagel-international-ag-1658763/eu-press-release/2020/02/25/12/20/41/78190/
PIDAY MEANING FRIDAY LOL
3. Coronavirus Spike Protein: Promising Immunogen for Universal Vaccine Development
The trimetric S-protein of coronaviruses is the reason for the crown shape of the viral particles, from which the name of the virus was given [20]. This structural protein belongs to class I viral fusion proteins and plays essential roles in the cell receptor binding, host tissue tropism and, pathogenesis. S-protein is cleaved at the S1/S2 site by host cell proteases during infection. Following cleavage, the protein is divided into an S1-ectodomain that recognizes a cognate cell surface receptor and an S2-membrane-anchored protein involved in viral entry [21]. The S1-protein contains a receptor-binding domain (RBD), which recognizes the angiotensin-converting enzyme 2 (ACE2) as one of the main receptors in the host [22]. RBD contains receptor-binding motif (RBM) that makes all the contacts with ACE2 and RBD core that is mostly conserved among coronaviruses [21, 23]. Binding of the RBD to the ACE2 receptor provokes S2 conformational changes [24]. S2 contains membrane-anchoring, fusion peptide, and two heptad repeat domains (HR1 and HR2), which plays a key role in virus assembly and entry (Figure 1) [25–27]. The studies showed that vaccines based on S-protein can evoke the immune system to induce humoral and cellular responses and protect vaccinated animals from SARS viral challenges (Table 1) [17, 28–32].
https://www.hindawi.com/journals/jir/2020/7201752/
I like HA!! :)
MYMX Stock Forecast, Price & News (Mymetics) | MarketBeat
www.marketbeat.com › stocks › OTCMKTS
Mymetics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021. View our earnings forecast for Mymetics. How has Mymetics' stock price been impacted by Coronavirus?
https://www.marketbeat.com/stocks/OTCMKTS/MYMX/earnings/#
(PDF) Recent trends in vaccine delivery systems: A review
www.researchgate.net › publication › 232257539
between the virosome and the antigen of interest is a prerequisite . for the full adjuvant effect of virosomes. Hence, virosomes . ... The novel betacoronavirus, SARS-CoV-2 (severe acute ..
Reddy College of Pharmacy, Hyderabad
https://www.researchgate.net/publication/232257539_Recent_trends_in_vaccine_delivery_systems_A_review
Recombinant protein vaccines, a proven approach against ...
www.sciencedirect.com › science › article
Mar 01, 2021 · SARS-CoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice bioRxiv ( 2020 ) , 10.1101/2020.11.04.367359
Author: Jeroen Pollet, Wen-Hsiang Chen, Ulrich Strych
Cited by: 1
https://www.sciencedirect.com/science/article/pii/S0169409X21000016
MILLIPLEX® Multiplex Assays for Research Applications in ...
www.sigmaaldrich.com › life-science › immunoassay
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice: Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice
https://www.sigmaaldrich.com/life-science/immunoassay-platform-solutions/milliplex/milliplex-multiplex-assays-for-research-applications.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162195235
Sarah Catherine Gilbert is a British vaccinologist who is Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. en.wikipedia.org
Prof. Dr. Matthias A. Hediger
Membrane Transport Discovery Lab
Head of the Lab
Department of Nephrology and Hypertension
Inselspital, University of Bern
Kinderklinik, Office D845, Freiburgstrasse 15
CH-3010 Bern
Switzerland
This project aims to decipher biological and pharmaceutical aspects of the SARS-CoV-2 virus pandemic. Using a combination of biochemical assays such as micro-scale thermophoresis (MST) to determine SARS-CoV-2 receptor binding domain (RBD) binding affinity to the ACE2 virus receptor and the SARS-CoV-2 pseudovirus entry assay to reveal viral load, we will clarify the roles of specific allelic variants of viral host genes in conferring COVID-19 severity. In addition, we will screen for blockers of viral susceptibility as hit/lead compounds for the development of novel treatment strategies.
The figure on the right shows the steps involved in SARS-CoV-2 infection in epithelial cells of lung, intestine and kidney, and project strategy outline. Using a combination of binding and pseudovirus entry assays, we will determine the effects of genetic host and viral variants on virus infectivity. Furthermore, we will screen for blockers of viral infection that may serve as future hit/lead compounds for the development of novel antiviral therapies, e.g. by administering identified agents using an oral or nasal spray, as an alternative to COVID-19 vaccination. Abbreviations: ACE2, angiotensin-converting enzyme 2 (serves as virus receptor); TMPRSS2, transmembrane protease (activates SARS-CoV-2); SLC6-AAT, SLC6 family amino acid transporter (transports peptide cleavage products of ACE2 into epithelial cells).
https://www.bioparadigms.org/hedigerlab/index.html
I real like your post BRO!! :)
Virus vaccines: proteins prefer prolines Rogier Sanders :)
Author links open overlay panel Rogier W.Sanders1 2 John P.Moore1
1
Department of Microbiology and Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA
2
Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, the Netherlands
Available online 10 March 2021.
Stabilized pre-fusion trimers from RSV and HIV-1 are now in clinical trials, with promising data emerging on the antibody response to RSV F. The SARS-CoV-2 S protein-based vaccines created during 2020 usually incorporate the dual-proline modification that can be traced back, first to the I559P change made to the HIV-1 Env trimer in 2002 and from there, to stabilization work on RSV F, MERS-CoV S, and other class I fusion proteins.
https://www.sciencedirect.com/science/article/pii/S1931312821000482
One vaccine is based on a yeast-derived (Pichia pastoris) recombinant protein comprised of the receptor binding domain (RBD) of the SARS-CoV formulated on alum and referred to as the CoV RBD219-N1 Vaccine. Potentially this vaccine could be used as a heterologous vaccine against COVID-19.
https://www.preprints.org/manuscript/202003.0464/v1
heterologous vaccine a vaccine that confers protective immunity against a pathogen that shares cross-reacting antigens with the microorganisms in the vaccine.
https://medical-dictionary.thefreedictionary.com/heterologous+vaccine
One vaccine is based on a yeast-derived (Pichia pastoris) recombinant protein comprised of the receptor binding domain (RBD) of the SARS-CoV formulated on alum and referred to as the CoV RBD219-N1 Vaccine. Potentially this vaccine could be used as a heterologous vaccine against COVID-19.
https://www.preprints.org/manuscript/202003.0464/v1
heterologous vaccine a vaccine that confers protective immunity against a pathogen that shares cross-reacting antigens with the microorganisms in the vaccine.
https://medical-dictionary.thefreedictionary.com/heterologous+vaccine